Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies [Phase 1]
Phase 1 study update for Orca-T in recipients undergoing allogeneic transplantation for hematologic malignancies; the trial is currently act…
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)
A clinical trial update describing the Unified platform for a better integral evaluation of Myelodysplastic Syndromes in Spain (UMBRELLA-SUM…
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) [Phase 3]
A Phase 3 clinical trial (ACROBAT) investigates the feasibility of allogeneic stem cell transplantation in patients with higher-risk myelody…
-
CLINICAL_TRIALS other · 2025-04-29Clinical Trial Update: MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing [NA]
Clinical trial update from the Medical College of Wisconsin describes a study using targeted antithymocyte globulin dosing to deplete alpha/…
-
CLINICAL_TRIALS withdrawal · 2025-04-29Clinical Trial Update: Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome
A clinical trial investigating physical activity in transfusion-dependent patients with myelodysplastic syndrome has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-04-27Clinical Trial Update: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) [Phase 3]
Phase 3 clinical trial evaluating Lemzoparlimab in combination with azacitidine versus azacitidine alone in higher-risk myelodysplastic synd…
-
CLINICAL_TRIALS research · 2025-04-24Clinical Trial Update: Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes [Phase 2]
A Phase 2 clinical trial is evaluating total body irradiation and cladribine as conditioning before allogeneic hematopoietic cell transplant…
-
CLINICAL_TRIALS research · 2025-04-23Clinical Trial Update: Study of REM-422 in Patients With AML or Higher Risk MDS [Phase 1]
Remix Therapeutics is conducting a Phase 1 study of REM-422 in patients with myelodysplastic syndromes and acute myeloid leukemia, including…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation [Phase 2]
Phase 2 trial evaluating tocilizumab to prevent graft-versus-host disease after cord blood transplantation has been completed.
-
CLINICAL_TRIALS research · 2025-04-22Clinical Trial Update: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia [Phase 2]
This entry describes a Phase 2 clinical trial evaluating matched unrelated donor versus haploidentical donor approaches for allogeneic stem …
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome [Phase 3]
A Phase 3 trial evaluating tamibarotene plus azacitidine in newly diagnosed RARA-positive higher-risk myelodysplastic syndromes was terminat…
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies [EARLY_Phase 1]
Early-phase clinical trial evaluating epigenetic therapy with azacitidine and decitabine for myeloid malignancies; the study is currently re…
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML [Phase 2]
Phase 2 clinical trial evaluating salvage therapy with venetoclax and decitabine for relapsed/refractory acute myeloid leukemia. The study a…
-
CLINICAL_TRIALS trial_result · 2025-04-07Clinical Trial Update: Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) [Phase 3]
A Phase 3 clinical trial comparing two dietary interventions in patients undergoing hematopoietic stem cell transplant or remission inductio…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation [Phase 1]
Phase 1 study evaluating itacitinib for prophylaxis of graft-versus-host disease and cytokine release syndrome after T-cell replete haploide…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant [EARLY_Phase 1]
An early-phase 1 clinical trial is evaluating hyperbaric oxygen therapy in combination with allogeneic peripheral blood stem cell transplant…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL
This completed observational study assessed the impact of newly started treatment on quality of life in patients with myelodysplastic syndro…
-
CLINICAL_TRIALS research · 2025-03-27Clinical Trial Update: Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia [Phase 1]
A Phase 1 study of eltanexor with venetoclax for relapsed or refractory myelodysplastic syndromes and acute myeloid leukemia is currently re…
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation [Phase 2]
Phase 2 clinical trial evaluating an anti-NKG2A monoclonal antibody in Acute Myeloid Leukemia or Myelodysplastic Syndromes patients undergoi…
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia [Phase 3]
A Phase 3 trial comparing oral decitabine/cedazuridine with azacitidine in myelodysplastic syndromes, acute myeloid leukemia with low blast …
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies [NA]
A clinical trial update examining whether CDA and/or dCK metabolizing enzymes influence the response to azacitidine in patients with hematol…
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes [Phase 1]
Phase 1 trial update for ASTX727 in lower-risk myelodysplastic syndromes indicates the study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 study of FF-10501-01 in relapsed or refractory hematologic malignancies has completed, with results posted. The diseases studied i…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS) [NA]
A clinical trial is investigating ferroptosis-targeting approaches in SF3B1-mutant myelodysplastic syndromes, and the study is currently rec…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Characterization of the Mechanisms of Resistance to Azacitidine
This clinical trial is investigating the mechanisms underlying resistance to azacitidine. It targets patients with myelodysplastic syndromes…